BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed...

|About: BioMimetic Therapeutics, Inc. (BMTI)|By:, SA News Editor

BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed bone-graft device, Augment, wouldn't be approved without more information from previous studies. The company says it plans to submit the necessary information by the middle of the year. Shares -10.7% AH.